750 related articles for article (PubMed ID: 23786539)
1. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
[TBL] [Abstract][Full Text] [Related]
2. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
3. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
4. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
5. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria.
Sanni LA; Thomas SR; Tattam BN; Moore DE; Chaudhri G; Stocker R; Hunt NH
Am J Pathol; 1998 Feb; 152(2):611-9. PubMed ID: 9466588
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Mazarei G; Leavitt BR
J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
[TBL] [Abstract][Full Text] [Related]
7. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
9. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
10. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
11. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.
Larkin PB; Sathyasaikumar KV; Notarangelo FM; Funakoshi H; Nakamura T; Schwarcz R; Muchowski PJ
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2345-2354. PubMed ID: 27392942
[TBL] [Abstract][Full Text] [Related]
14. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
Boros FA; Klivényi P; Toldi J; Vécsei L
Expert Opin Ther Targets; 2019 Jan; 23(1):39-51. PubMed ID: 30449219
[TBL] [Abstract][Full Text] [Related]
16. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
Laugeray A; Launay JM; Callebert J; Surget A; Belzung C; Barone PR
Behav Brain Res; 2010 Jun; 210(1):84-91. PubMed ID: 20153778
[TBL] [Abstract][Full Text] [Related]
17. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.
Thomas SR; Stocker R
Redox Rep; 1999; 4(5):199-220. PubMed ID: 10731095
[TBL] [Abstract][Full Text] [Related]
18. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.
Too LK; Li KM; Suarna C; Maghzal GJ; Stocker R; McGregor IS; Hunt NH
Behav Brain Res; 2016 Oct; 312():102-17. PubMed ID: 27316339
[TBL] [Abstract][Full Text] [Related]
19. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
Front Immunol; 2020; 11():55. PubMed ID: 32117235
[TBL] [Abstract][Full Text] [Related]
20. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Guidetti P; Bates GP; Graham RK; Hayden MR; Leavitt BR; MacDonald ME; Slow EJ; Wheeler VC; Woodman B; Schwarcz R
Neurobiol Dis; 2006 Jul; 23(1):190-7. PubMed ID: 16697652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]